NCT05617508View on ClinicalTrials.gov

N-DOSE AD: a Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 22, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions
Alzheimer DiseaseDementia
Interventions
OTHER

Placebo

Placebo capsules administered twice daily for a total of 12 weeks.

DIETARY_SUPPLEMENT

Nicotinamide Riboside supplementation 1000mg daily in total

Nicotinamide Riboside supplementation 1000mg daily in total

DIETARY_SUPPLEMENT

Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)

Nicotinamide Riboside supplementation up to 3000mg daily in total

Trial Locations (2)

5009

Haraldsplass Deaconess Hospital, Bergen

5021

Haukeland University Hospital, Bergen

All Listed Sponsors
collaborator

Haraldsplass Deaconess Hospital

OTHER

lead

Haukeland University Hospital

OTHER